[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367572-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367572-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","apobec3-mutagenesis-drives-therapy-resistance-in-breast-cancer","APOBEC3 mutagenesis drives therapy resistance in breast cancer","","Acquired genetic alterations limit long-term disease control in metastatic breast cancer, yet the mutational processes behind them remain insufficiently characterized. Using a clinically annotated cohort of 3,880 tumor-normal sequenced patient samples, mutational signatures linked to APOBEC3 enzymes were prevalent and enriched after treatment in ER-positive cancers. These signatures associated with shorter progression-free survival on antiestrogen plus CDK4/6 inhibitor therapy. Whole-genome and primary-metastatic model analyses showed active APOBEC3 mutagenesis promotes resistance via characteristic alterations, such as RB1 loss, establishing APOBEC3 as a biomarker and potential target to overcome resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/apobec3-mutagenesis-drives-therapy-resistance-in-breast-cancer/367572/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/apobec3-mutagenesis-drives-therapy-resistance-in-breast-cancer/367572.png","ImageObject",300,407,{"name":42,"@type":43},"Melati","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What data set was used to study APOBEC3 mutational processes in breast cancer?","Question",{"text":63,"@type":64},"A clinically annotated cohort of 3,880 patient samples with tumor-normal sequencing was analyzed, with detailed treatment and follow-up information.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were APOBEC3-linked mutational signatures related to treatment outcomes?",{"text":68,"@type":64},"APOBEC3-associated mutational signatures were enriched in post-treatment hormone receptor-positive cancers and correlated with shorter progression-free survival on antiestrogen plus CDK4/6 inhibitor therapy.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental evidence supports APOBEC3 mutagenesis as a driver of therapy resistance?",{"text":72,"@type":64},"Whole-genome sequencing of breast cancer models and paired primary-metastatic samples showed that active APOBEC3 mutagenesis promotes therapy resistance through characteristic alterations such as RB1 loss.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367572,1790893462,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","nature genetics  \nArticle [https://doi.org/10.1038/s41588-025-02187-1](https://doi.org/10.1038/s41588-025-02187-1)  \n\n| APOBEC3 mutagenesis drives therapy resistance in breast cancer |  |  |\n| --- | --- | --- |\n| Received: 8 May 2024\u003Cbr>Accepted: 1 April 2025\u003Cbr>Published online: 16 May 2025  Check for updates | Avantika Gupta  1,10, Andrea Gazzo2,10, Pier Selenica2, AntonSafonov3,\u003Cbr>Fresia Pareja  2, Edaise M. da Silva  2, David N. Brown  2, Hong Shao1, Yingjie Zhu  2, Juber Patel2, Juan Blanco-Heredia  2, Bojana Stefanovska  4,5, Michael A. Carpenter  4,5, Yanjun Chen4, Isabella Vegas  1, Xin Pei  6, Denise Frosina2, AchimA. Jungbluth2, Marc Ladanyi  2,\u003Cbr>Giuseppe Curigliano  7,8, Britta Weigelt  2, Nadeem Riaz  6,\u003Cbr>Simon N. Powell  6, Pedram Razavi  3,9, ReubenS. Harris  4,5,\u003Cbr>Jorge S. Reis-Filho2, Antonio Marra  2,7,8  & SaratChandarlapaty  1,3,9 \u003Cbr>Acquired genetic alterations drive resistance to endocrine and targeted therapies in metastatic breast cancer; however, the underlying processes engendering these alterations are largely uncharacterized. To identify the underlying mutational processes, we utilizeda clinically annotated cohort of 3,880 patient samples with tumor-normal sequencing.\u003Cbr>Mutational signatures associated with apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) enzymes were prevalent and enriched in post-treatment hormone receptor-positive cancers.\u003Cbr>These signatures correlated with shorter progression-free survival on antiestrogen plus CDK4/6 inhibitor therapy in hormone receptor-positive metastatic breast cancer. Whole-genome sequencing of breast cancer models and paired primary-metastatic samples demonstrated that active APOBEC3 mutagenesis promoted therapy resistance through characteristic alterations such as RB1 loss. Evidence of APOBEC3 activity in pretreatment samples illustrated its pervasive role in breast cancer evolution. These studies reveal APOBEC3 mutagenesisto bea frequent mediator of therapy resistance in breast cancer and highlight its potential asa biomarker and target for overcoming resistance. |  |\n| Both endocrine and targeted therapies are used broadly to treat breast cancer; however, their potential for long-term disease control is limited by tumor evolution and acquired genetic alterations that promote drug resistance1. In estrogen receptor (ER)-positive cancers, alterations in several genes including ER (ESR1)2,3, neurofibromin (NF1)4,5 and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, or HER2)6 are common as tumors develop resistance to antiestrogen therapy. Such genetic alterations also occur after resistance to targeted therapies including cyclin dependent kinase 4/6 inhibitors (CDK4/6i), human epidermal growth factor receptor 2 (HER2) |  | inhibitors and phosphoinositide 3-kinase (PI3K) inhibitors7–12. The widespread prevalence of these heterogeneous and acquired genetic alterations has proven challenging to overcome despite the development of second-generation inhibitors such as selective ER degraders (SERDs), underscoring the need to understand the underlying processes of genomic instability and tumor evolution.\u003Cbr>Detailed analyses of cancer genomes have identified mutational signatures that can promote tumor evolution, and potentially predict treatment strategies13–15. In breast cancer, single base substitution (SBS) signatures associated with the activity of APOBEC3 enzymes (COSMIC |\n| A full list of affiliations appears at the end of the paper. e-mail: [antonio.marra@ieo.it](antonio.marra@ieo.it); [chandars@mskcc.org](chandars@mskcc.org) |  |  |\n\nNature Genetics | Volume 57 | June 2025 | 1452–1462 1452  \nSBS2 and SBS13) are prevalent, suggesting their relevance to the underlying genomic instability. APOBEC3 proteins are cytidine deaminases that play roles in innate immunity by restricting viral replication and inhibiting retrotransposition16. Although APOBEC3 enzymes serve as protective factors against viral i","cbCaiv1Jt3pa3Ny6","https://ap.wps.com/l/cbCaiv1Jt3pa3Ny6","pdf",11879727,29,"English","# Abstract / Overview\n# Background: resistance in metastatic breast cancer\n# APOBEC3 mutational signatures and clinical associations\n# Experimental evidence from models and primary-metastatic samples\n# Results: APOBEC3 mutagenesis in metastatic and treatment-resistant breast cancers","[{\"question\":\"What data set was used to study APOBEC3 mutational processes in breast cancer?\",\"answer\":\"A clinically annotated cohort of 3,880 patient samples with tumor-normal sequencing was analyzed, with detailed treatment and follow-up information.\"},{\"question\":\"How were APOBEC3-linked mutational signatures related to treatment outcomes?\",\"answer\":\"APOBEC3-associated mutational signatures were enriched in post-treatment hormone receptor-positive cancers and correlated with shorter progression-free survival on antiestrogen plus CDK4/6 inhibitor therapy.\"},{\"question\":\"What experimental evidence supports APOBEC3 mutagenesis as a driver of therapy resistance?\",\"answer\":\"Whole-genome sequencing of breast cancer models and paired primary-metastatic samples showed that active APOBEC3 mutagenesis promotes therapy resistance through characteristic alterations such as RB1 loss.\"}]","APOBEC3 mutagenesis drives therapy resistance in breast cancer | PDF",1790171427,73,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa2e4f1e96cf8b80b76974fcc345c189.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/358866898eca55f7ad16fdb54f08e910.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fc9a99f2cf80a1ad0e2b4dbe9036706.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7563e5f7600e67564c6ad012f689139a.webp",980,1301]